Status:
COMPLETED
An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Targacept Inc.
Conditions:
ADHD
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
A 3-way cross-over trial of two weeks of treatment with three drug conditions. AZD3480 will be given in doses of (A) 5mg/day, (B) 50 mg/day and (C) placebo to 24 non-smoking adults with DSM-IV confirm...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of DSM-IV ADHD
- Score of equal or more than 2 on at least six of nine items in at least one of the subscales of the Connor´s Adult ADHD Rating Scale (CAARS-INV)
- Score of equal or more than 4 (at least moderate severity) on the Clinical Global Impressions-Severity (CGI-S) test
Exclusion
- Current DSM-IV Axis I psychiatric disorder (other than ADHD)
- Current user of cigarettes or other nicotine-containing product.
- Slow metabolizers as indicated by CYP2D6 genotyping.
- Use of drugs affecting cognitive function within 8 weeks prior to enrollment visit or intended use during the study.
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00683462
Start Date
May 1 2008
End Date
July 1 2009
Last Update
October 30 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Burlington, Vermont, United States